Legis
Healthcare
California bill · Sunday 27 September 2026
AB 1887
Chapter 557, Statutes of 2026

Prescription drug coverage for rare diseases

Starting in 2027, plans and insurers must act within 30 days on prior authorization for certain sole FDA-approved rare-disease drugs.

Patients with rare diseases may receive automatic approval when a plan or insurer delays a decision or an authorization dispute remains unresolved after 30 days.

What the law does ​

  • Applies to health plan contracts and insurance policies issued, amended, or renewed on or after January 1, 2027.
  • Requires prior-authorization decisions within 30 days of the initial request for an FDA-approved drug that is the only FDA-approved treatment for a rare disease.
  • Limits the protection to drugs prescribed by a specialist with relevant expertise who determines the drug is medically necessary.
  • Requires immediate approval if no decision is made within 30 days or a dispute remains ongoing at that deadline.
  • Defines a rare disease as one affecting fewer than 200,000 people in the United States.
  • Excludes Medi-Cal managed care contracts.

Who it affects ​

  • Patients with qualifying rare diseases.
  • Specialists and their staff submitting prior-authorization requests.
  • Health care service plans and health insurers.

Context ​

Existing faster prior-authorization timelines remain unchanged.